Symrise AG (ETR:SY1)
103.75
+0.85 (0.83%)
May 9, 2025, 5:35 PM CET
Symrise AG Revenue
In the year 2024, Symrise AG had annual revenue of 5.00B EUR with 5.67% growth. Symrise AG had revenue of 2.43B in the half year ending December 31, 2024, with 3.18% growth.
Revenue
5.00B
Revenue Growth
+5.67%
P/S Ratio
2.88
Revenue / Employee
394.48K
Employees
12,956
Market Cap
14.38B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 5.00B | 268.33M | 5.67% |
Dec 31, 2023 | 4.73B | 111.71M | 2.42% |
Dec 31, 2022 | 4.62B | 792.79M | 20.72% |
Dec 31, 2021 | 3.83B | 305.24M | 8.67% |
Dec 31, 2020 | 3.52B | 112.60M | 3.30% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BASF SE | 65.11B |
Heidelberg Materials AG | 21.25B |
Covestro AG | 14.15B |
Evonik Industries AG | 15.16B |
Brenntag SE | 16.24B |
Wacker Chemie AG | 5.71B |
K+S Aktiengesellschaft | 3.65B |
LANXESS Aktiengesellschaft | 6.37B |
Symrise AG News
- 9 days ago - EQS-PVR: Symrise AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution - Wallstreet:Online
- 10 days ago - Symrise Shines: Strong Q1 Growth & Steady Outlook - Wallstreet:Online
- 10 days ago - EQS-News: Symrise delivers solid growth in Q1 and reaffirms outlook - Wallstreet:Online
- 5 weeks ago - EQS-PVR: Symrise AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution - Wallstreet:Online
- 2 months ago - EQS-News: Symrise accelerates in Human Health and Pet Nutrition through a strategic partnership with HBC - Wallstreet:Online
- 2 months ago - Hofseth Biocare ASA: HBC ACCELERATES IN HUMAN HEALTH AND PET NUTRITION THROUGH A STRATEGIC PARTNERSHIP WITH SYMRISE TO BUILD OUT BERKÅK, TRIPLING THE MANUFACTURING CAPACITY OF THE GROUP - GlobeNewsWire
- 3 months ago - EQS-DD: Symrise AG: Dr. Stephanie Coßmann, buy - Wallstreet:Online
- 3 months ago - EQS-DD: Symrise AG: Olaf Klinger, buy - Wallstreet:Online